Assessing the cost-effectiveness of postmastectomy radiation therapy
Identifieur interne : 00AF30 ( Main/Exploration ); précédent : 00AF29; suivant : 00AF31Assessing the cost-effectiveness of postmastectomy radiation therapy
Auteurs : Lawrence B. Marks [États-Unis] ; Patricia H. Hardenbergh [États-Unis] ; Eric T. Winer [États-Unis] ; Leonard R. Prosnitz [États-Unis]Source :
- International Journal of Radiation Oncology, Biology, Physics [ 0360-3016 ] ; 1999.
English descriptors
- KwdEn :
Abstract
Purpose: To assess the cost-effectiveness of postmastectomy local-regional radiation therapy (RT) for patients with breast cancer with regard to local-regional relapse (LRR) and quality-adjusted life years (QALY). Methods and Materials: Data from the literature are used to estimate the risk of LRR, and the impact of RT on the risk of LRR and survival. The risk of LRR is related linearly to the number of positive axillary nodes [% rate of LRR = 10 + (4 × number of positive nodes)]. RT reduces the risk of LRR by 67%. LRRs are treated with excision or biopsy followed by RT; half being controlled locally and half receiving additional salvage surgery and chemotherapy. Absolute improvements in 10-year overall survival due to RT are assumed to vary between 1 and 12%; and accrue linearly during the initial 10-year follow-up period. Professional and technical charges are used as a surrogate for costs. Money spent and benefits recognized in future years are discounted to 1997 values using a 3% annual rate. Quality factors are used to adjust for treatment, disease, and toxicity status. Results: The cost per LRR prevented with the addition of routine postmastectomy RT is highly dependent upon the number of positive axillary nodes and ranges from $100,000–$200,000 for patients with 0–2 nodes, and $25,000–$75,000 for ≥ 4 nodes. The cost per QALY gained at 10 years is $10,000–$110,000 for survival benefits ≥ 3%. Conclusions: The cost per LRR prevented decreases with increasing numbers of positive axillary nodes. There is not a sharp cutoff at the ≤3 vs. ≥4 lymph node number, suggesting that using this cutoff for recommending or not recommending RT following mastectomy is not economically logical. The cost per QALY of $10,000–$100,000 compares favorably to that of other accepted medical procedures. Modest changes in the quantitative assumptions do not qualitatively alter the results. Concerns regarding costs should not generally preclude the use of postmastectomy RT.
Url:
DOI: 10.1016/S0360-3016(98)00520-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 007501
- to stream Istex, to step Curation: 007501
- to stream Istex, to step Checkpoint: 003851
- to stream Main, to step Merge: 00B548
- to stream Main, to step Curation: 00AF30
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessing the cost-effectiveness of postmastectomy radiation therapy</title><author><name sortKey="Marks, Lawrence B" sort="Marks, Lawrence B" uniqKey="Marks L" first="Lawrence B" last="Marks">Lawrence B. Marks</name></author><author><name sortKey="Hardenbergh, Patricia H" sort="Hardenbergh, Patricia H" uniqKey="Hardenbergh P" first="Patricia H" last="Hardenbergh">Patricia H. Hardenbergh</name></author><author><name sortKey="Winer, Eric T" sort="Winer, Eric T" uniqKey="Winer E" first="Eric T" last="Winer">Eric T. Winer</name></author><author><name sortKey="Prosnitz, Leonard R" sort="Prosnitz, Leonard R" uniqKey="Prosnitz L" first="Leonard R" last="Prosnitz">Leonard R. Prosnitz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F93D7BC6BD911A3D4A2C8C8229AEF3775976E9BD</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1016/S0360-3016(98)00520-3</idno><idno type="url">https://api.istex.fr/document/F93D7BC6BD911A3D4A2C8C8229AEF3775976E9BD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">007501</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">007501</idno><idno type="wicri:Area/Istex/Curation">007501</idno><idno type="wicri:Area/Istex/Checkpoint">003851</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">003851</idno><idno type="wicri:doubleKey">0360-3016:1999:Marks L:assessing:the:cost</idno><idno type="wicri:Area/Main/Merge">00B548</idno><idno type="wicri:Area/Main/Curation">00AF30</idno><idno type="wicri:Area/Main/Exploration">00AF30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Assessing the cost-effectiveness of postmastectomy radiation therapy</title><author><name sortKey="Marks, Lawrence B" sort="Marks, Lawrence B" uniqKey="Marks L" first="Lawrence B" last="Marks">Lawrence B. Marks</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hardenbergh, Patricia H" sort="Hardenbergh, Patricia H" uniqKey="Hardenbergh P" first="Patricia H" last="Hardenbergh">Patricia H. Hardenbergh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Winer, Eric T" sort="Winer, Eric T" uniqKey="Winer E" first="Eric T" last="Winer">Eric T. Winer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gillette Center for Women’s Cancers, Dana Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Prosnitz, Leonard R" sort="Prosnitz, Leonard R" uniqKey="Prosnitz L" first="Leonard R" last="Prosnitz">Leonard R. Prosnitz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Radiation Oncology, Biology, Physics</title><title level="j" type="abbrev">ROB</title><idno type="ISSN">0360-3016</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1999">1999</date><biblScope unit="volume">44</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="91">91</biblScope><biblScope unit="page" to="98">98</biblScope></imprint><idno type="ISSN">0360-3016</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-3016</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benefit</term><term>Breast cancer</term><term>Charges</term><term>Cost</term><term>Effectiveness</term><term>Postmastectomy</term><term>Radiation therapy</term><term>Utility</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To assess the cost-effectiveness of postmastectomy local-regional radiation therapy (RT) for patients with breast cancer with regard to local-regional relapse (LRR) and quality-adjusted life years (QALY). Methods and Materials: Data from the literature are used to estimate the risk of LRR, and the impact of RT on the risk of LRR and survival. The risk of LRR is related linearly to the number of positive axillary nodes [% rate of LRR = 10 + (4 × number of positive nodes)]. RT reduces the risk of LRR by 67%. LRRs are treated with excision or biopsy followed by RT; half being controlled locally and half receiving additional salvage surgery and chemotherapy. Absolute improvements in 10-year overall survival due to RT are assumed to vary between 1 and 12%; and accrue linearly during the initial 10-year follow-up period. Professional and technical charges are used as a surrogate for costs. Money spent and benefits recognized in future years are discounted to 1997 values using a 3% annual rate. Quality factors are used to adjust for treatment, disease, and toxicity status. Results: The cost per LRR prevented with the addition of routine postmastectomy RT is highly dependent upon the number of positive axillary nodes and ranges from $100,000–$200,000 for patients with 0–2 nodes, and $25,000–$75,000 for ≥ 4 nodes. The cost per QALY gained at 10 years is $10,000–$110,000 for survival benefits ≥ 3%. Conclusions: The cost per LRR prevented decreases with increasing numbers of positive axillary nodes. There is not a sharp cutoff at the ≤3 vs. ≥4 lymph node number, suggesting that using this cutoff for recommending or not recommending RT following mastectomy is not economically logical. The cost per QALY of $10,000–$100,000 compares favorably to that of other accepted medical procedures. Modest changes in the quantitative assumptions do not qualitatively alter the results. Concerns regarding costs should not generally preclude the use of postmastectomy RT.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Marks, Lawrence B" sort="Marks, Lawrence B" uniqKey="Marks L" first="Lawrence B" last="Marks">Lawrence B. Marks</name></region><name sortKey="Hardenbergh, Patricia H" sort="Hardenbergh, Patricia H" uniqKey="Hardenbergh P" first="Patricia H" last="Hardenbergh">Patricia H. Hardenbergh</name><name sortKey="Prosnitz, Leonard R" sort="Prosnitz, Leonard R" uniqKey="Prosnitz L" first="Leonard R" last="Prosnitz">Leonard R. Prosnitz</name><name sortKey="Winer, Eric T" sort="Winer, Eric T" uniqKey="Winer E" first="Eric T" last="Winer">Eric T. Winer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00AF30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00AF30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F93D7BC6BD911A3D4A2C8C8229AEF3775976E9BD
|texte= Assessing the cost-effectiveness of postmastectomy radiation therapy
}}
| This area was generated with Dilib version V0.6.31. |  |